drugset / Trial / NCT02587650
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib, regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2015-03-26
- Primary completion
- 2018-07-12
- Completion
- 2018-07-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capmatinib | Small molecule | — | Oral |
| Subject | Ceritinib | Small molecule | — | Oral |
| Subject | Entrectinib | Small molecule | — | Oral |
| Subject | Regorafenib | Small molecule | — | Oral |